Enterprise Europe Network
HomeParticipantsMarketplace

ProductUpdated on 19 November 2025

Factor B and protein C2 point mutants, a method of enhancing the activity of anti-cancer antibodies, the pharmaceutical composition and the use of mutants

Innovation Broker | Project Coordinator at Medical University of Gdańsk - Technology Transfer Office

Gdańsk, Poland

About

The subject of the offer is an invention allowing us to enhance the cytotoxic activity of antibody-based drugs used, among others, to fight haematological malignancies. A patent was awarded to this invention in Poland, bearing number Pat.237868 and in the United States with the number USAppl.np.17/045058.

Similar opportunities

  • Investment

    Bioreplica Spinal Device

    • Startup
    • Seed and Development
    • BIOLOGY / BIOTECHNOLOGY
    • INTELLECTUAL PROPERTY, LEGAL AND FINANCIAL SERVICES

    Rodrigo de Pablos

    CEO at Bioreplica

    Las Palmas, Spain

  • Product

    VAX-ID

    • MEDICINE
    • LIFE SCIENCE
    • THERAPEUTIC AREA
    • Re-Seller/Wholesaler
    • BIOLOGY / BIOTECHNOLOGY

    Vanessa Vankerckhoven

    CEO | Founder at Idevax

    Antwerp, Belgium

  • Product

    Synthesis of lipopeptide conjugates in the treatment of chronic wounds

    Marcin Stolarek

    Innovation Broker | Project Coordinator at Medical University of Gdańsk - Technology Transfer Office

    Gdańsk, Poland